TLDR:
- Ocugen reports Phase 1 GARDian1 results showing OCU410ST slows lesion growth.
- Treated eyes gained +6 letters in visual acuity; untreated eyes declined.
- No drug-related serious adverse events observed in 12-month trial period.
- Phase 2/3 GARDian3 trial on track for Q1 2026 enrollment completion.
- OCU410ST uses gene-agnostic RORA therapy to target Stargardt disease pathways.
Ocugen, Inc. (OCGN) stock closed near $2.38 after the company published positive Phase 1 GARDian1 trial results.
Ocugen, Inc., OCGN
The results report 12-month safety and efficacy outcomes for OCU410ST, its modifier gene therapy for Stargardt disease. The data highlight structural improvements and functional gains in treated eyes compared to untreated fellow eyes.
The Phase 1 trial evaluated patients across early to advanced Stargardt disease stages. Six patients had gradable Fundus Auto Fluorescence images and six were BCVA-evaluable without confounders. Results showed atrophic lesion growth reduced by 54% in treated eyes and a +6 letter gain in visual acuity.
No drug-related serious adverse events or adverse events of special interest occurred during the study. Treated eyes either stabilized or improved in all cases. The findings support further clinical development of OCU410ST and progression to Phase 2/3 trials.
Positive Outcomes and Functional Gains
Lesion expansion was 50% slower in treated eyes than untreated eyes over 12 months. The rate was below published natural history rates for Stargardt disease progression. Functional outcomes aligned with structural benefits, confirming the therapy’s modifier potential.
All treated eyes maintained or improved visual acuity, while untreated eyes showed a decline. The therapy acts independent of ABCA4 genotype, providing a gene-agnostic treatment approach. OCU410ST demonstrates convergent functional and structural improvements critical for long-term disease management.
The data represent the first human evidence of modifier gene therapy effectiveness in Stargardt disease. The outcomes validate the safety and tolerability of OCU410ST. They also reinforce the platform’s potential to slow disease progression and improve vision.
Phase 2/3 GARDian3 Trial and Next Steps
The Phase 2/3 GARDian3 trial is ahead of schedule with enrollment expected to finish in Q1 2026. The company plans a Biologics License Application (BLA) filing in H1 2027. This aligns with Ocugen’s broader strategy to advance multiple regulatory submissions in three years.
OCU410ST delivers the RORA gene using an AAV5 platform, addressing oxidative stress, inflammation, and photoreceptor survival networks. The therapy targets key Stargardt disease pathways, including lipofuscin accumulation and complement activation. The approach provides potential lifelong benefits regardless of underlying genetic mutations.
Ocugen continues to focus on advancing blindness therapies globally. The results highlight the company’s gene-agnostic approach to rare eye diseases. This milestone positions Ocugen to expand development and provide hope to patients with no current disease-modifying options.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
